Nanalysis Scientific Corp. is pleased to announce that it has shipped the first four units of its new 100 MHz product to customers. Current sales backlog of this product is over $4.5 million and growing. Dr. Susanne Riegel Director of Marketing states "When Nanalysis entered the benchtop NMR market, we quickly identified the customer need for such a high-end product. Based on years of customer feedback, we have ...

Nanalysis Scientific Corp. (Nanalysis, TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ), is pleased to announce that it has shipped the first four units of its new 100 MHz product to customers. Current sales backlog of this product is over $4.5 million and growing.

Dr. Susanne Riegel , Director of Marketing states "When Nanalysis entered the benchtop NMR market, we quickly identified the customer need for such a high-end product. Based on years of customer feedback, we have refined our product specifications and are excited to release this innovative product to address the demand.  It has been extremely well received and I am excited about its potential in pharma, biotech, flavour and fragrance, personal care, advanced materials, security, energy, and many other sectors and end markets."

Neal Gallagher , Director of Product Development states "When marketing challenged our team to develop the highest performing permanent magnet platform possible, it became immediately clear that we had to throw out the standard playbook and start our thinking from scratch. This approach allowed us to really push the envelope in terms of considering how magnetic, mechanical, electrical, and thermal systems could interact. We overcame numerous materials and technical challenges along the way culminating in the strongest most sensitive compact permanent magnet platform in history. Never before has any organization been able to establish a stable magnetic field of over 2.3 Tesla of spectroscopic quality on the benchtop and I think our devotion to every aspect of the product will shine through in the customer experience.

I am very proud of our magnet, electronics, software, and system integration teams. Together, I believe we have achieved a landmark new product, and our customers agree. We will continue to create the most advanced products that enable our customers to solve ever more exciting problems using NMR and create the chemistry of the future - We are just getting started! "

Sean Krakiwsky , founder and CEO of Nanalysis Scientific added, "Now that this product is shipping to customers, I expect it to provide strong revenue growth going forward. Our sales team and distributor network are very excited about this product. Our manufacturing department has capacity to fulfill the current order backlog in the near term and the sales pipeline for the rest of the year is strong. Our Calgary and Strasbourg teams worked incredibly well together on this project. The first critical test of our ability to integrate RS2D's Cameleon4 TM technology from last March's acquisition and enhance our MRI and NMR technology platform was a resounding success."

About Nanalysis Scientific Corp. ( TSXV: NSCI , OTCQX: NSCIF, FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol ' NSCI ' ,Over the Counter (OTC) in the United States under the ticker symbol ' NSCIF ', and on the Frankfurt Exchange (FRA) under the symbol ' 1N1 '.

Nanalysis is an international business focused on capitalizing its proprietary technologies in nuclear magnetic resonance (NMR) that go into NMR spectrometers and magnetic resonance imaging (MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp. and RS2D S.A.S. (RS2D).

Nanalysis Corp. is an industry leader in developing and manufacturing compact NMR spectrometers for laboratory and industrial markets. Its cutting edge 60 and 100 MHz spectrometers require no liquid helium or other cryogens. Its spectrometers are used by chemical professionals spanning industries, including, but not limited to, oil and gas, chemical, mining, pharmaceutical, and biotechnology.

Through its European subsidiary RS2D, the Company electronic boards and software used to drive MRI equipment in pre-clinical configurations and are being incorporated into next-gen MRI systems.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2021/05/c3608.html

News Provided by Canada Newswire via QuoteMedia

KWESST Micro Systems Taps AMW PR to Lead Public Relations, Media Strategy Initiatives

KWESST Micro Systems Taps AMW PR to Lead Public Relations, Media Strategy Initiatives

National U.S. Public Relations Firm Will Bring KWESST's Story and Proprietary Systems to Media, Public Markets

KWESST Micro Systems Inc. (OTCQB: KWEMF) (TSXV: KWE) ("KWESST," or "the Company"), a leader in providing next-generation tactical systems for security forces and personal defense, is pleased to announce that it has engaged the New York-based public relations firm AMW Public Relations to lead the Company's public relations, brand strategy, and media communications initiatives.

Keep reading... Show less
OTC Markets Group Welcomes ProStar Holdings Inc to OTCQX

OTC Markets Group Welcomes ProStar Holdings Inc to OTCQX

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced ProStar Holdings Inc (TSX-V: MAPS;  OTCQX: MAPPF), a leader in Precision Mapping Solutions, has qualified to trade on the OTCQX® Best Market. ProStar upgraded to OTCQX from the OTCQB® Venture Market.

ProStar begins trading today on OTCQX under the symbol "MAPPF."  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .

Keep reading... Show less
InvestmentPitch Media Video Discusses Cloud DX's Selection by Medtronic for Canada-Wide Remote Patient Monitoring - Video Available on Investmentpitch.com

InvestmentPitch Media Video Discusses Cloud DX's Selection by Medtronic for Canada-Wide Remote Patient Monitoring - Video Available on Investmentpitch.com

Cloud DX Inc. (TSXV: CDX) (OTCQB: CDXFF) has been selected by Medtronic Canada ULC, to provide world-class virtual healthcare to Medtronic's patients across Canada. Medtronic Canada, (www.medtronic.ca) headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver, is the largest medical technology company in Canada, and a subsidiary of Medtronic plc (NYSE: MDT), a multi billion-dollar, global leader in medical technology, offering medical devices and therapies to more than 72 million people across 150 countries.

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news and the company, along with comments from Robert Kaul, CEO of Cloud DX, about the significance of this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Cloud DX" in the search box.

Keep reading... Show less
The Power Play by The Market Herald Releases New Interviews with Cloud DX, Reklaim, Pacific Ridge and Legible

The Power Play by The Market Herald Releases New Interviews with Cloud DX, Reklaim, Pacific Ridge and Legible

The Power Play by The Market Herald has announced the release of new interviews with Cloud DX, Reklaim, Pacific Ridge and Legible discussing their latest press releases

The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

Keep reading... Show less

Nanalysis to Present at December Investor Conferences

Nanalysis Scientific Corp. ("Nanalysis", TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ) will be presenting at three upcoming investor conferences in December. We encourage shareholders to listen in and book meetings in order to stay up to date with our developments.

Keep reading... Show less
Cloud DX selected by Medtronic for national collaboration

Cloud DX selected by Medtronic for national collaboration

Medtronic selected Cloud DX for virtual and remote patient monitoring (RPM) solutions in exclusive corporate agreement

Cloud DX (TSXV: CDX) (OTCQB: CDXFF) has been selected by Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), a global leader in healthcare technology, to provide world-class virtual healthcare to patients across Canada . This partnership advances Medtronic's commitment to improving patient outcomes and lowering overall costs along the care continuum. Cloud DX's remote patient monitoring (RPM) technology and services are exclusive to Medtronic and its Canadian client base, which is spread across Canada. Medtronic Canada delivers care in a broad range of clinical areas, including spinal and cardiac surgeries, cardiology, critical care, diabetes, vascular and renal care. Most clinical areas are expected to improve patient outcomes and satisfaction with some aspect of virtual care in the future. Initially, Medtronic seeks to integrate the Connected Health TM platform and associated services within both perioperative and complex chronic disease pathways in Canada .

Keep reading... Show less

Top News

Related News